Mirum Pharmaceuticals, Inc. (MIRM)Healthcare | Biotechnology | Foster City, United States | NasdaqGM
79.62 USD
-6.44
(-7.483%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 10:31 a.m. EDT
Mirum Pharmaceuticals presents a classic biotech dichotomy: a fundamentally robust growth story currently under pressure from technicals and near-term execution risks. The long-term trajectory is undeniable, with a 671% cumulative gain over six years driven by five consecutive years of positive annual returns and a 38% revenue surge. Fundamentally, the company boasts healthy gross margins above 80% and generated positive free cash flow of $76 million, supported by a strong liquidity position despite negative earnings typical of the sector. However, the short-term outlook is clouded by a 10% decline from the 50-day average and a recent 6% slide over two weeks, coinciding with deepening losses despite higher guidance. While analysts maintain a strong buy stance with a mean target implying nearly 70% upside, the options market is pricing in near-term volatility with elevated implied volatility and a put-heavy skew for October expiration, suggesting institutional hedging. Investors should view the current weakness as a potential accumulation opportunity given the strong underlying business metrics and FDA designations, rather than a fundamental deterioration. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.055309 |
| MSTL | 0.524529 |
| AutoETS | 0.531052 |
| AutoARIMA | 0.901686 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 7.92 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.026 |
| Excess Kurtosis | -0.36 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 11.016 |
| Market Cap | 5,169,902,080 |
| Forward P/E | -229.67 |
| Beta | 0.62 |
| Profit Margins | -139.18% |
| Website | https://www.mirumpharma.com |
As of Oct. 10, 2026, 10:31 a.m. EDT: Speculators are positioning for near-term volatility with elevated implied volatility and a defensive put skew for October expiration, suggesting hedging against downside risk. For later 2026 and 2027 expiries, the market shows a bullish bias with out-of-the-money call open interest dominating, indicating bets on a recovery or continued upside.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.12954462 |
| Address1 | 989 East Hillsdale Boulevard |
| Address2 | Suite 300 |
| All Time High | 130.0 |
| All Time Low | 6.513 |
| Ask | 134.63 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 950,720 |
| Average Daily Volume3 Month | 714,674 |
| Average Volume | 714,674 |
| Average Volume10Days | 950,720 |
| Beta | 0.615 |
| Bid | 76.76 |
| Bid Size | 2 |
| Board Risk | 10 |
| Book Value | -0.161 |
| City | Foster City |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 79.62 |
| Current Ratio | 2.856 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 87.0 |
| Day Low | 79.51 |
| Display Name | Mirum Pharmaceuticals |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,961,800 |
| Earnings Call Timestamp Start | 1,785,961,800 |
| Earnings Timestamp | 1,785,960,000 |
| Earnings Timestamp End | 1,793,822,400 |
| Earnings Timestamp Start | 1,793,822,400 |
| Ebitda | -70,283,000 |
| Ebitda Margins | -0.11371 |
| Enterprise To Ebitda | -78.178 |
| Enterprise To Revenue | 8.89 |
| Enterprise Value | 5,494,560,256 |
| Eps Current Year | -15.14 |
| Eps Forward | -0.34667 |
| Eps Trailing Twelve Months | -14.1 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 94.7809 |
| Fifty Day Average Change | -15.160896 |
| Fifty Day Average Change Percent | -0.15995729 |
| Fifty Two Week Change Percent | 12.954462 |
| Fifty Two Week High | 130.0 |
| Fifty Two Week High Change | -50.379997 |
| Fifty Two Week High Change Percent | -0.38753843 |
| Fifty Two Week Low | 63.232 |
| Fifty Two Week Low Change | 16.388004 |
| Fifty Two Week Low Change Percent | 0.25917265 |
| Fifty Two Week Range | 63.232 - 130.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,563,456,600,000 |
| Float Shares | 56,351,412 |
| Forward Eps | -0.34667 |
| Forward P E | -229.67087 |
| Free Cashflow | 76,618,128 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 433 |
| Fullday Change | -6.149994 |
| Fullday Change Percent | -7.14617 |
| Fullday Price | 79.62 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.81725 |
| Gross Profits | 505,112,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01314 |
| Held Percent Institutions | 1.1185501 |
| Implied Shares Outstanding | 64,932,203 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California. |
| Long Name | Mirum Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 5,169,902,080 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_590571226 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -860,206,976 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 5,802,341,660 |
| Number Of Analyst Opinions | 14 |
| Open | 86.06 |
| Operating Cashflow | -227,267,008 |
| Operating Margins | -0.1481 |
| Overall Risk | 9 |
| Phone | 650 667 4085 |
| Previous Close | 86.06 |
| Price Eps Current Year | -5.258917 |
| Price Hint | 2 |
| Price To Book | -494.53418 |
| Price To Sales Trailing12 Months | 8.364631 |
| Profit Margins | -1.39177 |
| Quick Ratio | 2.62 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.28571 |
| Region | US |
| Regular Market Change | -6.43999 |
| Regular Market Change Percent | -7.48315 |
| Regular Market Day High | 87.0 |
| Regular Market Day Low | 79.51 |
| Regular Market Day Range | 79.51 - 87.0 |
| Regular Market Open | 86.06 |
| Regular Market Previous Close | 86.06 |
| Regular Market Price | 79.62 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 762,442 |
| Return On Assets | -0.067930005 |
| Return On Equity | -7.02967 |
| Revenue Growth | 0.379 |
| Revenue Per Share | 11.016 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 64,932,203 |
| Shares Percent Shares Out | 0.1076 |
| Shares Short | 6,985,385 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 6,171,979 |
| Short Name | Mirum Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.1385 |
| Short Ratio | 9.65 |
| Source Interval | 15 |
| State | CA |
| Symbol | MIRM |
| Target High Price | 200.0 |
| Target Low Price | 118.0 |
| Target Mean Price | 151.64285 |
| Target Median Price | 149.0 |
| Total Cash | 438,291,008 |
| Total Cash Per Share | 6.75 |
| Total Debt | 762,948,992 |
| Total Revenue | 618,067,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -14.1 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 98.501274 |
| Two Hundred Day Average Change | -18.881271 |
| Two Hundred Day Average Change Percent | -0.19168556 |
| Type Disp | Equity |
| Volume | 762,442 |
| Website | https://www.mirumpharma.com |
| Zip | 94,404 |